Suvretta Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $56M | Buy |
4,955,000
+41,988
| +0.9% | +$475K | 1.69% | 18 |
|
|
2025
Q1 | $56.7M | Hold |
4,913,012
| – | – | 2.1% | 13 |
|
|
2024
Q4 | $41.6M | Buy |
4,913,012
+701,007
| +17% | +$5.94M | 1.42% | 23 |
|
|
2024
Q3 | $48.8M | Buy |
4,212,005
+20,000
| +0.5% | +$232K | 1.56% | 23 |
|
|
2024
Q2 | $49.4M | Hold |
4,192,005
| – | – | 1.81% | 16 |
|
|
2024
Q1 | $49.7M | Buy |
4,192,005
+1,508,000
| +56% | +$17.9M | 1.85% | 15 |
|
|
2023
Q4 | $32.9M | Buy |
2,684,005
+263,154
| +11% | +$3.22M | 1.49% | 25 |
|
|
2023
Q3 | $23.3M | Buy |
2,420,851
+386,345
| +19% | +$3.72M | 1.26% | 26 |
|
|
2023
Q2 | $18.3M | Buy |
2,034,506
+51,327
| +3% | +$462K | 0.98% | 37 |
|
|
2023
Q1 | $15.6M | Buy |
1,983,179
+910,877
| +85% | +$7.16M | 0.66% | 41 |
|
|
2022
Q4 | $7.25M | Sell |
1,072,302
-634,798
| -37% | -$4.29M | 0.3% | 53 |
|
|
2022
Q3 | $24.8M | Sell |
1,707,100
-221,100
| -11% | -$3.21M | 1.03% | 39 |
|
|
2022
Q2 | $19M | Buy |
1,928,200
+181,900
| +10% | +$1.79M | 0.72% | 46 |
|
|
2022
Q1 | $25.7M | Hold |
1,746,300
| – | – | 0.79% | 41 |
|
|
2021
Q4 | $23.1M | Buy |
1,746,300
+203,016
| +13% | +$2.69M | 0.45% | 47 |
|
|
2021
Q3 | $26.9M | Buy |
1,543,284
+352,183
| +30% | +$6.15M | 0.45% | 44 |
|
|
2021
Q2 | $28.5M | Buy |
1,191,101
+231,209
| +24% | +$5.54M | 0.43% | 52 |
|
|
2021
Q1 | $24.7M | Buy |
959,892
+650,992
| +211% | +$16.7M | 0.36% | 53 |
|
|
2020
Q4 | $5.87M | Hold |
308,900
| – | – | 0.08% | 72 |
|
|
2020
Q3 | $3.89M | Buy |
308,900
+61,900
| +25% | +$779K | 0.07% | 67 |
|
|
2020
Q2 | $2.99M | Buy |
247,000
+132,800
| +116% | +$1.61M | 0.06% | 63 |
|
|
2020
Q1 | $874K | Buy |
+114,200
| New | +$874K | 0.02% | 53 |
|